Jonzobot

Granted - there has not been much dilution from the Covid trial alone that us investors are aware of, however, it has been 5 months since RVX has published a financial statement. At 9/30/21, RVX had an accumulated shareholders deficit of ~ 44mil - add to that 6mil + 10% accrued interest to get the IP out of hock, the liabilities at 9/30/21, the cost of the Covid trial, 5 mos of operating and G&A expenses- you are looking at 100 mil - that's before funding a 3600 patient BOM2 trial and operations for another 2-3 years to get to an interim analysis. Also looming is a Covid Phase3 and a BetonRenal trial. 

A Covid-19 failure will cut the market value of this stock in half and place RVX in a tenuous bargaining position while strapped for cash.

Resverlogix needs to generate revenue - very soon. Covid-19 EUA or a buyout.

jmo

chicagoest